QIAGEN Reports Strong Third Quarter 2009 Results

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




  * 16% Revenue Growth on Constant Exchange Rates
  * 15% Organic Revenue Growth
  * 31% Operating Margin, adjusted
  * $0.26 Adjusted EPS

Venlo, The Netherlands, November 9, 2009 - QIAGEN N.V. (Nasdaq: QGEN;
Frankfurt, Prime  Standard:  QIA)  today  announced  the  results  of
operations for  the third  quarter and  the nine-month  period  ended
September 30, 2009.

The reported net sales  and the adjusted earnings  per share for  the
third quarter 2009 exceeded the  guidance provided by the Company  on
August 11, 2009.

Third Quarter 2009 Results


QIAGEN's Third Quarter 2009 (in US$ millions, except per share
information)
                                         Q3 2009    Q3 2008    Growth

Net sales                                  259.7      230.8      13 %
Net sales at constant exchange rates       268.7      230.8      16 %
Operating income, adjusted                  81.8       66.8      22 %
Net income, adjusted                        53.5       42.4      26 %
EPS, adjusted (US$)                         0.26       0.21      24 %

For information on the adjusted figures, please refer to the
reconciliation table
accompanying this release.


The Company  reported  that  consolidated net  sales  for  its  third
quarter 2009 increased 13% to  $259.7 million from $230.8 million  in
the same  quarter  of 2008.  Excluding  the unfavorable  impact  from
foreign currency exchange rates, net sales for the third quarter 2009
would have  increased  16%. The  reported  operating income  for  the
quarter increased 40% to $53.4 million from $38.2 million in the same
quarter of 2008,  and net  income for  the quarter  increased 81%  to
$37.7 million from $20.8 million in the same quarter of 2008. Diluted
earnings per share for  the third quarter increased  80% to $0.18  in
2009 from $0.10 in 2008.

On an adjusted basis, third quarter operating income increased 22% to
$81.8 million in 2009 from $66.8  million in 2008, and third  quarter
2009 adjusted net income  increased 26% to  $53.5 million from  $42.4
million in 2008. Adjusted diluted earnings per share increased 24% to
$0.26 in the third quarter 2009 from $0.21 in 2008.

Nine-Month Period 2009 Results

For the  nine-month  period  ended  September  30,  2009,  net  sales
increased 10% to  $720.7 million  compared to $655.8  million in  the
same period of 2008. Operating income as reported for the nine months
ended September 30, 2009 increased 30% to $137.3 million from  $105.2
million for the  same period  in 2008.  Net income  increased 45%  to
$93.3 million from $64.4  million in 2008,  and diluted earnings  per
share increased 45% to $0.45 in 2009 from $0.31 in 2008.

On an  adjusted basis,  operating income  for the  nine-month  period
ended September 30, 2009 increased 14% to $212.7 million in 2009 from
$186.1 million  in 2008,  and adjusted  net income  increased 19%  to
$142.0 million  from $119.6  million. Adjusted  diluted earnings  per
share in the nine  months ended September 30,  2009 increased 19%  to
$0.69 per share from $0.58 per share in the same period of 2008.

QIAGEN's third quarter and nine-month period 2009 results include the
results of  operations from  the Company's  recent acquisitions,  the
most significant of which was  DxS Ltd., acquired in September  2009,
and Corbett Life Science, acquired  in July 2008. Reconciliations  of
reported results  determined in  accordance with  generally  accepted
accounting principles (GAAP) to adjusted results are included in  the
tables accompanying this release.

"We are  very pleased  with our  financial performance  in the  third
quarter of 2009," said Peer Schatz, QIAGEN's Chief Executive Officer.
"We saw strong growth in revenues, operating margins and adjusted net
income - all of which exceeded our guidance. In addition, our organic
revenue growth came in very strong at 15%."

"Revenue growth  was  highest  in sales  to  customers  in  molecular
diagnostics (approximately 50% of  total revenues) followed by  sales
to customers  in pharma  (approximately 21%  of total  revenues),  in
applied testing (approximately 6% of total revenues) and in  academia
(approximately 23%  of  total  revenues).  Growth  of  our  sales  to
customers in molecular diagnostics was fueled by strong sales of  our
"prevention" products (primarily HPV screening),"personalized  health
care" assays  (including our  KRAS testing  solutions) and  profiling
solutions (including  our  influenza  and  other  infectious  disease
assays).  Sales  to  customers  in  the  pharmaceutical  and  biotech
industry conducting  clinical  development  continued  to  experience
solid  growth  and  sales  to  customers  in  pharma  discovery   are
improving. The academic research markets continued to perform solidly
and we are  looking forward to  the effect of  the stimulus  programs
which are expected for 2010."

"The markets we serve demonstrated  robust demand and solid  economic
trends. We are very pleased with the strategic momentum we were  able
to build  since the  announcement of  our second  quarter results  in
August. Since August we have announced the following acquisitions:

  * The pending acquisition of SABiosciences will add to QIAGEN a
    portfolio of PCR-based, pathway-focused panels that represent
    highly efficient solutions for pathway- and disease-biomarker
    discovery and development in pharmaceutical and biomedical
    research. The efforts associated with the validation of such
    biomarkers can at the same time serve as engines for novel
    content for molecular diagnostics.

  * The acquisition of DxS Ltd. combines two leadership positions to
    create a very powerful leader in a transformational area of
    healthcare: personalized healthcare.

Both transactions  are  key  elements  of our  strategy  to  lead  in
molecular diagnostics-based  prevention, profiling  and  personalized
healthcare. These three pillars of our molecular diagnostics strategy
are  expected  to  significantly  shape  and  contribute  to   future
improvements  in  healthcare  and  have  the  potential  to   provide
significant benefits to  patients as  well as  exceptional value  for
payers, providers, and the pharmaceutical industry."

"QIAGEN experienced a successful third quarter. Reported revenues and
adjusted earnings per share  exceeded our expectations," said  Roland
Sackers,  QIAGEN's  Chief   Financial  Officer.  "Assuming   constant
exchange rates for both quarters,  and adjusted for the divesture  of
certain  assets  related  to   our  activities  in  HLA   diagnostics
(transplantation diagnostics), revenue growth was 18% and was  fueled
by a strong organic growth of  15% and a positive contribution of  3%
from acquisitions.

Our consumable  products portfolio  contributed  12% growth  (16%  at
constant exchange rates)  and our sales  of instrumentation  products
recorded a growth rate of 18%  (23% at constant exchange rates).  Net
sales  in  the  Americas  for  the  third  quarter  2009  represented
approximately 51% of our overall business and recorded a growth  rate
of 12% (15%  at constant  exchange rates) and  European sales,  which
represent approximately 35% of our revenues, showed a growth rate  of
16% (24%  at constant  exchange rates).  Net sales  in Asia  remained
strong, showing  a  growth rate  of  41% (37%  at  constant  exchange
rates)."

Increase of Fiscal Year 2009 Guidance Range

Based on the successful first nine months and a positive outlook  for
the rest  of the  year,  QIAGEN is  increasing its  expectations  for
adjusted diluted earnings per share for the fiscal year 2009 from the
previous range of $0.86 to $0.90 (based on a weighted average  number
of fully  diluted shares  outstanding  of approximately  214  million
following the equity offering in September 2009) to now between $0.88
and $0.90 based on foreign currency exchange rates as of January  31,
2009.

QIAGEN - Sample and Assay Technologies Highlights

  * In September, QIAGEN acquired DxS Ltd., a developer and
    manufacturer of companion diagnostic products (CDx) for
    Personalized Healthcare (PHC). With this acquisition, QIAGEN has
    added to its own activities in CDx and taken a strong leadership
    position in the new era of PHC. The Company believes it offers
    all the required elements to help drive and shape this rapidly
    emerging trend in healthcare. The acquisition of DxS brings to
    QIAGEN a portfolio of molecular diagnostic assays and
    intellectual property, as well as a deep pipeline of active or
    planned companion diagnostic partnerships in oncology with many
    of the leading pharmaceutical companies, including Amgen,
    Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca and
    others. These assets complement QIAGEN's strong existing
    portfolio of personalized healthcare diagnostic solutions and are
    very synergistic with QIAGEN's sample and assay technologies.

  * In November, QIAGEN announced that it is in the process of
    acquiring SABiosciences. This transaction will add to QIAGEN's
    product offering a leading portfolio of PCR-based, disease and
    pathway-based panels that play key roles in biomedical research
    and the development of future drugs and diagnostics. The
    offerings from SABiosciences can significantly increase QIAGEN's
    footprint in the rapidly emerging segment of molecular
    analysis-based clinical development in pharmaceutical and
    biomedical research. In addition, the use of these panels and the
    resulting validation of select biomarkers from these panels by
    institutions conducting biomedical and pharmaceutical research
    has the potential to serve as a unique engine to support the
    expansion of the test menu for QIAGEN's diagnostics platforms -
    in particular in the area of personalized health care but also in
    prevention and profiling. As such, this transaction is highly
    synergistic with QIAGEN's activities in the fast growing segments
    of solutions for pharmaceutical development and molecular
    diagnostics.

  * In September, QIAGEN and Merck & Co., Inc. announced the creation
    of a joint program to increase access to HPV vaccination and HPV
    DNA testing in some of the poorest areas of the world. This
    initiative is the first collaboration of a vaccine manufacturer
    and a molecular diagnostics company to address the burden of
    cervical cancer with a comprehensive approach. Representing a
    combined value of approximately $600 million based on current
    U.S. prices, the commitments of QIAGEN and Merck were highlighted
    among a select group of corporate initiatives announced at the
    annual meeting of the Clinton Global Initiative in September.
    QIAGEN intends to add to its existing one million test donation
    program by providing the digene HC2 HPV DNA Test (as known as the
    digene HPV Test) and a new HPV DNA test that is currently in
    development for use specifically in the developing world to
    screen an additional 500,000 women. In addition, Merck intends to
    provide up to five million free doses of its cervical cancer
    vaccine, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6,
    11, 16 and18) Vaccine Recombinant].

  * In September, QIAGEN opened its new Asia headquarters in
    Zhangjiang High-Tech Park, Pudong, Shanghai, China. QIAGEN
    established Shanghai as the location for its Asia headquarters in
    2006. Resources and employees that were previously spread across
    different locations have been brought together at the new site in
    Zhangjiang High-Tech Park - which has emerged as the
    biotechnology hub of China. Zhangjiang High-Tech Park is home to
    15 multinational pharmaceutical R&D centers, 32 Contract Research
    Organization (CRO) companies, 29 major pharma manufacturing
    plants and over 200 biotech-pharma companies. QIAGEN's new
    facility provides better access to the Company's new technologies
    and applications and reduces delivery time to thousands of
    scientists working in the Park.

  * In the first nine months of 2009, QIAGEN launched more than 48
    new products in the area of Sample & Assay Technologies including
    a range of applications used to analyze genetic differences
    between individuals or cells, the Type-it® HRM PCR Kit and
    Rotor-Gene® ScreenClust HRM Software. HRM (high resolution
    melting) technology enabling fast, accurate genotyping results.
    In addition QIAGEN launched a new PCR-based Influenza A/H1N1 test
    that enables both the highly sensitive and specific detection of
    the novel Influenza A/H1N1, the virus that causes "swine flu", as
    well as of all other known Influenza A and B virus strains and
    several QIAsafe DNA Blood Products, the first dry blood storage
    solutions available on a matrix, based on Biomatrica's innovative
    SampleMatrix® technology.

  * In September, QIAGEN placed 31.6 million shares (including the
    full exercise of an over-allotment option) at a price of $20.25
    per share. QIAGEN used and expects to use the net proceeds of
    approximately $624 million to fund the acquisition of DxS Ltd. as
    well as potential future acquisitions, to strengthen its balance
    sheet and for general corporate purposes.

  * In October, QIAGEN started the relocation of its activities in
    Brisbane and Sydney to other locations of the Company, primarily
    to QIAGEN Instruments AG in Switzerland. The restructurings
    follow the acquisition of Corbett in 2008 and consolidate
    QIAGEN's instrument manufacturing activities. The closure and
    relocation is intended to be completed in the second quarter of
    2010 and is expected to result in an increase in QIAGEN's future
    profitability. QIAGEN expects to incur total restructuring
    charges of approximately $4 to $5 million before taxes for the
    remainder of fiscal 2009 and fiscal 2010.

Conference Call and Webcast Details

Detailed information on QIAGEN's  business and financial  performance
will be presented during its conference call on November 10, 2009  at
9:30am ET. The  corresponding presentation slides  will be  available
for     download      on      the      Company's      website      at
www.qiagen.com/goto/ConferenceCall. A webcast of the conference  call
will also be available at www.qiagen.com/goto/ConferenceCall.

Use of Adjusted Results

QIAGEN has  regularly reported  adjusted results  to give  additional
insight into its financial performance as well as considered  results
on a constant currencies basis. Adjusted results should be considered
in addition  to  the reported  results  prepared in  accordance  with
generally  accepted  accounting   principles,  but   should  not   be
considered as a substitute. The Company believes certain items should
be excluded  from  adjusted results  when  they are  outside  of  its
ongoing core operations, vary significantly from period to period, or
affect the comparability  of results with  the Company's  competitors
and its own  prior periods.  Reconciliations of  reported results  to
adjusted  results  are  included  in  the  tables  accompanying  this
release.
About QIAGEN

QIAGEN N.V., a  Netherlands holding  company, is  the leading  global
provider of sample  and assay technologies.  Sample technologies  are
used to isolate  and process  DNA, RNA and  proteins from  biological
samples such as blood or tissue. Assay technologies are used to  make
these isolated biomolecules visible. QIAGEN has developed and markets
more than  500  sample  and  assay  products  as  well  as  automated
solutions for such consumables. The Company provides its products  to
molecular    diagnostics    laboratories,    academic    researchers,
pharmaceutical  and  biotechnology  companies,  and  applied  testing
customers for purposes such as forensics, animal or food testing  and
pharmaceutical process control.  QIAGEN's assay technologies  include
one of the  broadest panels of  molecular diagnostic tests  available
worldwide. This panel includes the first FDA-approved test for  human
papillomavirus (HPV), the  primary cause of  cervical cancer.  QIAGEN
employs more  than  3,300  people in  over  30  locations  worldwide.
Further    information    about    QIAGEN    can    be    found    at


http://www.qiagen.com/.

Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics markets, women's  health/HPV testing markets,  nucleic
acid-based molecular diagnostics market, and genetic vaccination  and
gene  therapy   markets,  changing   relationships  with   customers,
suppliers and strategic  partners, competition,  rapid or  unexpected
changes in technologies, fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the level
and timing of  customers' funding, budgets,  and other factors),  our
ability to  obtain  regulatory  approval of  our  infectious  disease
panels, difficulties in  successfully adapting  QIAGEN's products  to
integrated solutions  and producing  such  products, the  ability  of
QIAGEN to identify and develop new products and to differentiate  its
products from competitors'  products, market  acceptance of  QIAGEN's
new  products  and  the  integration  of  acquired  technologies  and
businesses. In  addition certain  statements contained  in this  news
release are based on company assumptions, including, but not limited,
to revenue  allocations  based  on  business  segments.  For  further
information, refer  to the  discussions in  reports that  QIAGEN  has
filed with,  or  furnished  to,  the  U.S.  Securities  and  Exchange
Commission (SEC).
                                # # #


                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)

                                                     Three months
(in thousands, except per share data)             ended September 30,

                                                    2009       2008
Net sales                                       $  259,659 $  230,800
   Cost of sales                                    86,647     77,861
Gross profit                                       173,012    152,939

Operating expenses:
   Research and development                         26,747     24,073
   Sales and marketing                              60,719     55,972
   General and administrative, integration and
other                                               27,805     29,868
   Purchased in-process research and
development                                              -        830
   Acquisition related intangible amortization       4,387      4,018
Total operating expenses                           119,658    114,761

Income from operations                              53,354     38,178

Other income (expense):
   Interest income                                     678      2,095
   Interest expense                                (7,405)    (9,194)
   Other income, net                                 2,692    (3,233)
Total other expense                                (4,035)   (10,332)

Income before provision for income taxes and
noncontrolling interest                             49,319     27,846
Provision for income taxes                          11,629      6,679
Net income                                          37,690     21,167
Less: Noncontrolling interest                            -        376
Net income attributable to QIAGEN N.V.          $   37,690 $   20,791

   Weighted average number of diluted common
shares                                             208,316    204,600

   Diluted net income attributable to QIAGEN    $          $
N.V. per common share                                 0.18       0.10

   Diluted net income attributable to QIAGEN
N.V. per common
   share, adjusted                              $     0.26 $     0.21




                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)


                                                      Nine months
(in thousands, except per share data)             ended September 30,

                                                    2009       2008
Net sales                                       $  720,748 $  655,794
   Cost of sales                                   241,787    213,555
Gross profit                                       478,961    442,239

Operating expenses:
   Research and development                         77,340     69,281
   Sales and marketing                             175,857    167,746
   General and administrative, integration and
other                                               76,210     88,672
   Purchased in-process research and
development                                              -        830
   Acquisition related intangible amortization      12,289     10,484
Total operating expenses                           341,696    337,013

Income from operations                             137,265    105,226

Other income (expense):
   Interest income                                   2,541      7,391
   Interest expense                               (22,136)   (28,832)
   Other income, net                                 5,249      (672)
Total other expense                               (14,346)   (22,113)

Income before provision for income taxes and
noncontrolling interest                            122,919     83,113
Provision for income taxes                          29,616     18,272
Net income                                          93,303     64,841
Less: Noncontrolling interest                            -        491
Net income attributable to QIAGEN N.V.          $   93,303 $   64,350

   Weighted average number of diluted common
shares                                             205,096    204,999

   Diluted net income attributable to QIAGEN
N.V. per common share                           $     0.45 $     0.31

   Diluted net income attributable to QIAGEN
N.V. per common
   share, adjusted                              $     0.69 $     0.58




                             QIAGEN N.V.
                CONDENSED CONSOLIDATED BALANCE SHEETS


(in thousands, except par value)           September 30,
                                               2009      December 31,
Assets                                      (unaudited)      2008

Current Assets:
Cash and cash equivalents                   $    861,273  $   333,313
Accounts receivable, net                         181,692      158,440
Income taxes receivable                           27,843       14,441
Inventories, net                                 133,618      108,563
Prepaid expenses and other                       135,192       61,424
Deferred income taxes                             32,543       27,374
Total current assets                           1,372,161      703,555

Long-Term Assets:
Property, plant and equipment, net               310,215      289,672
Goodwill                                       1,273,754    1,152,105
Intangible assets, net                           693,777      640,309
Deferred income taxes                             78,016       73,766
Other assets                                      26,728       25,916
Total long-term assets                         2,382,490    2,181,768

Total assets                                $  3,754,651  $ 2,885,323

Liabilities and Shareholders' Equity

Current Liabilities:
Accounts payable                            $     42,078  $    48,836
Accrued and other liabilities                    236,980      163,513
Income taxes payable                              33,414       14,288
Current portion of long-term debt                 50,000       25,000
Current portion of capital lease
obligations                                        3,342        2,984
Deferred income taxes                             10,256        7,754
Total current liabilities                        376,070      262,375

Long-Term Liabilities:
Long-term debt, net of current portion           870,000      920,000
Capital lease obligations, net of current
portion                                           28,797       29,718
Deferred income taxes                            237,530      212,589
Other                                             13,945        6,797
Total long-term liabilities                    1,150,272    1,169,104

Shareholders' Equity:
Common shares, EUR .01 par value:
Authorized--410,000 shares
Issued and outstanding--231,130 shares
in 2009 and 197,839 shares in 2008                 2,697        2,212
Additional paid-in-capital                     1,606,218      958,665
Retained earnings                                571,115      477,812
Accumulated other comprehensive income            48,279       15,155
Total QIAGEN N.V. shareholders' equity         2,228,309    1,453,844

Total liabilities and shareholders' equity  $  3,754,651  $ 2,885,323



                Three months ended September 30, 2009
                   (in thousands, except EPS data)



                  Net     Gross     Operating   Pre-tax               Net    Diluted
                 Sales   Profit      Income     Income  Income Tax  Income     EPS*

Reported
results       $ 259,659 $ 173,012 $    53,354 $  49,319 $ (11,629) $  37,690 $   0.18

Adjustments:
Business
integration,
acquisition
related
and
restructuring
costs                 -       177       2,790     2,790      (918)     1,872     0.01

Purchased
intangibles
amortization          -    13,111      17,499    17,499    (6,082)    11,417     0.06

Share-based
compensation          -       245       2,348     2,348      (678)     1,670     0.01

Acquisition
of DxS Ltd.           -     2,515       5,784     5,784    (1,661)     4,123     0.02
Transfer of
Olerup SSP
business and
other
acquisition
related
income                -         -           -   (2,429)      (835)   (3,264)   (0.02)

Total
adjustments           -    16,048      28,421    25,992   (10,174)    15,818     0.08

Adjusted
results       $ 259,659 $ 189,060 $    81,775 $  75,311 $ (21,803) $  53,508 $   0.26

Using 208,316
diluted
shares



                Three months ended September 30, 2008
                   (in thousands, except EPS data)


                          Gross   Operating Pre-tax               Net    Diluted
              Net Sales  Profit    Income    Income  Income Tax  Income   EPS*

Reported
results       $ 230,800 $ 152,939  $ 38,178 $ 27,846 $  (6,679) $ 20,791  $ 0.10

Adjustments:
Business
integration,
acquisition
related
and
restructuring
costs                 -       396     9,122    9,122    (3,138)    5,984    0.03

Purchased
in-process
R&D                   -         -       830      830          -      830       -

Purchased
intangibles
amortization          -    12,776    16,794   16,794    (5,876)   10,918    0.06

Share-based
compensation          -       223     1,896    1,896      (580)    1,316    0.01

Acquisition
related
impairment            -         -         -    4,000    (1,480)    2,520    0.01

Total
adjustments           -    13,395    28,642   32,642   (11,074)   21,568    0.11

Adjusted
results       $ 230,800 $ 166,334  $ 66,820 $ 60,488 $ (17,753) $ 42,359  $ 0.21



* Using 204,600 diluted shares



                             QIAGEN N.V.
           RECONCILIATION OF REPORTED TO ADJUSTED FIGURES
                             (unaudited)

                Nine months ended September 30, 2009
                   (in thousands, except EPS data)



                          Gross   Operating  Pre-tax                Net    Diluted
              Net Sales  Profit    Income    Income   Income Tax  Income     EPS*
Reported
results       $ 720,748 $ 478,961 $ 137,265 $ 122,919 $ (29,616) $  93,303 $   0.45

Adjustments:
Business
integration,
acquisition
related
and
restructuring
costs                 -       688    10,705    10,705    (3,396)     7,309     0.04

Purchased
intangibles
amortization          -    39,290    51,579    51,579   (17,973)    33,606     0.17
Share-based
compensation          -       699     7,352     7,352    (2,229)     5,123     0.02
Acquisition
of DxS Ltd.           -     2,515     5,784     5,784    (1,661)     4,123     0.02
Transfer of
Olerup SSP
business and
other
                      -
acquisition
related
income                          -         -   (2,429)      (835)   (3,264)   (0.02)
Acquisition
related
write-off of
prepaid
expenses and
other asset
impairment            -         -         -     2,703      (870)     1,833     0.01

Total
adjustments           -    43,192    75,420    75,694   (26,964)    48,730     0.24

Adjusted
results       $ 720,748 $ 522,153 $ 212,685 $ 198,613 $ (56,580) $ 142,033 $   0.69



* Using 205,096 diluted shares


                Nine months ended September 30, 2008
                   (in thousands, except EPS data)


                  Net     Gross     Operating   Pre-tax               Net    Diluted
                 Sales   Profit      Income     Income  Income Tax  Income    EPS*

Reported
results       $ 655,794 $ 442,239 $   105,226 $  83,113 $ (18,272) $  64,350  $ 0.31

Adjustments:
Business
integration,
acquisition
related
and
restructuring
costs                 -       396      27,723    27,723    (9,760)    17,963    0.09

Purchased
in-process
R&D                   -         -         830       830          -       830       -

Purchased
intangibles
amortization          -    35,551      46,035    46,035   (16,306)    29,729    0.15

Share-based
compensation          -       763       6,251     6,251    (2,001)     4,250    0.02

Acquisition
related
impairment            -         -           -     4,000    (1,480)     2,520    0.01

Total
adjustments           -    36,710      80,839    84,839   (29,547)    55,292    0.27

Adjusted
results       $ 655,794 $ 478,949 $   186,065 $ 167,952 $ (47,819) $ 119,642  $ 0.58

* Using
204,999
diluted
shares



Contacts:


Roland Sackers                          Dr. Solveigh Mähler
Chief Financial Officer                 Director Investor Relations
QIAGEN N.V.                             QIAGEN N.V.
e-mail:                                 [phone]
[e-mail]               e-mail:
                                        [e-mail]

                                        Albert F. Fleury
                                        Associate Director Investor
                                        Relations North America
                                        QIAGEN N.V.
                                        [phone]
                                        e-mail:
                                        [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;